In this episode (20:20), Medicom’s correspondent covers 6 presentations from the European Alliance of Associations for Rheumatology (EULAR 2022) annual meeting, held on-site in Copenhagen and virtual live from 1-4 June 2022, marking EULAR's 75th anniversary!
The topics discussed are:
- JAK inhibitor shows to be effective in non-radiographic axSpA
Once-daily therapy with upadacitinib led to an Assessment of SpondyloArthritis International Society 40 (ASAS40) response in 45% of patients with active, non-radiographic axial spondylarthritis (nr-axSpA) at week 14 in the SELECT-AXIS-2 trial. This was the first phase 3 trial data of JAK inhibitors ever presented in this indication. - Baricitinib shows great potential in juvenile idiopathic arthritis
During the double-blind period of a withdrawal trial, baricitinib demonstrated predominance over placebo in the prevention of disease flares. These occurred in more than half of the cases in the placebo group but only about 17% in the baricitinib group. - TYK2 inhibition: A rising star in lupus therapy?
Deucravacitinib showed convincing results as a treatment for patients with active systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial. Depending on the dosage, up to 58.2% of study drug recipients showed a Systemic Lupus Erythematosus Responder Index (SRI) 4 response, significantly more than on placebo. - Antifibrotic therapy effective in patients with negative prognostic factors for lung function decline
Previously, nintedanib has shown to slow lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial. A post-hoc analysis of this trial revealed that treatment benefit is also evident in patients with 4 characteristics associated with a fast decline in lung function. - Treatment with bimekizumab beneficial in psoriatic arthritis
The IL-17A/IL-17F blocker bimekizumab showed marked superiority in the primary and all ranked secondary endpoints of the phase 3 BE OPTIMAL trial as a therapy for psoriatic arthritis (PsA). At week 16, over 40% of study participants reached an ACR50 response. - IL-6 inhibition successful in treating polymyalgia rheumatica
Sarilumab demonstrated positive results in the randomised, phase 3 SAPHYR trial for patients with polymyalgia rheumatica (PMR). Significantly more participants reached sustained remission and the risk of flares was reduced.
Enjoy listening!
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Enzalutamide with active surveillance reduces prostate-cancer progression Next Article
Consensus on isotretinoin laboratory monitoring in acne treatment »
« Enzalutamide with active surveillance reduces prostate-cancer progression Next Article
Consensus on isotretinoin laboratory monitoring in acne treatment »
Table of Contents: EULAR 2022
Featured articles
Late-Breaking Oral Abstracts
TYK2 inhibition: the future of treating lupus erythematosus?
Psoriatic arthritis: significant improvement with bimekizumab
Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis
Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares
Spotlight on Rheumatoid Arthritis
Comorbid depression comes with a profoundly higher mortality risk in RA
Preventive treatment with methotrexate benefits pre-RA patients with arthralgia
Risk factors for dementia in RA patients discovered
VTE in global registry data more common in JAK inhibitor-treated RA patients
Spondyloarthropathies – Novel Developments
How to treat enthesitis in 2022
Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib
Treat-to-target dose reduction effective in spondyloarthritis
A novel oral treatment possibility for non-radiographic axSpA on the horizon
Many RA and PsA patients have problems with their sex life
What Is Hot in Osteoarthritis?
New treatments in osteoarthritis
OA associated with alcohol and drug abuse
Body mass index increase associated with structural changes in knee OA
What Is New in Lupus and Scleroderma
Inhibition of Bruton’s tyrosine kinase: a new way of approaching SLE?
Pregnancies in SLE: many complications for mothers and their unborn children
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement
Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors
Best of the Posters
Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease
High prevalence of fibromyalgia in patients with inflammatory bowel disease
Related Articles
May 9, 2019
ABX464: HIV drug tested in ulcerative colitis
October 27, 2021
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com